A PMCF Study Confirm the Performance and Safety of the TufTex Over-the-Wire (OTW) Embolectomy Catheters

Last updated: October 16, 2024
Sponsor: LeMaitre Vascular
Overall Status: Active - Recruiting

Phase

N/A

Condition

Claudication

Deep Vein Thrombosis

Circulation Disorders

Treatment

TufTex Over-the-Wire Embolectomy Catheter

Clinical Study ID

NCT05386342
EC-16-002
  • Ages > 18
  • All Genders

Study Summary

A PMCF study to confirm the performance and safety of the LeMaitre® TufTex Over-the-Wire Embolectomy Catheter

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male and female subject, ≥ 18 years of age at time of enrollment.

  2. Subject who is scheduled to undergo surgical treatment for the removal of an embolior thrombi during an embolectomy and/or thrombectomy procedure, where one of theLeMaitre® Embolectomy Catheter will be used.

  3. Subject signed an Informed Consent for participation.

  4. Subject diagnosed with a embolus/thrombus.

  5. Subjects for whom thrombolytic therapy had failed or was contraindicated.

Exclusion

Exclusion Criteria:

  1. Co-morbidity that in the discretion of the investigator might confound the results.

  2. Subjects who are unable to read or write.

  3. Pregnant or lactating women at time of enrollment

  4. Subjects who are immune compromised

Study Design

Total Participants: 112
Treatment Group(s): 1
Primary Treatment: TufTex Over-the-Wire Embolectomy Catheter
Phase:
Study Start date:
January 11, 2023
Estimated Completion Date:
June 30, 2027

Study Description

This clinical investigation is a prospective, single-arm, multicenter, post-market study to proactively collect clinical data on the LeMaitre® TufTex Over-the-Wire (OTW) Embolectomy Catheters and to confirm its performance in removing arterial emboli and/or thrombi, to identify and analyze emergent risks on the basis of factual evidence, and to ensure the continued acceptability of the benefit/risk ratio. The intended purpose of the device in this post market clinical study is identical to the indication of use of the device.

The TufTex OTW post-market study is initiated by the Sponsor and manufacturer of the device, LeMaitre Vascular, Inc.

The investigation will take place in 4 sites, most likely in 3 different countries. A total number of 112 subjects is anticipated to be enrolled, who are intended to undergo surgical treatment for the removal of a emboli and/or thrombi. The anticipated enrollment period is 48 months, and the participation per subject is 1 month. The total study duration is expected to be 56 months (4 months start-up, 48 months of recruitment, 1 month of follow-up, 3 months of closure.

Connect with a study center

  • Andrej Udelnow

    Brandenburg,
    Germany

    Active - Recruiting

  • University Hospital Carl Gustav Carus TU Dresden

    Dresden,
    Germany

    Site Not Available

  • Ospedale Regionale di Lugano - sede Civico

    Lugano,
    Switzerland

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.